MSJ-0011 + urinary hCG (u-hCG) + Follitropin alpha
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Anovulation
Conditions
Anovulation, Oligo-ovulation, Hypothalamic-pituitary Dysfunction, Polycystic Ovarian Syndrome
Trial Timeline
Sep 1, 2012 → Dec 1, 2014
NCT ID
NCT01653743About MSJ-0011 + urinary hCG (u-hCG) + Follitropin alpha
MSJ-0011 + urinary hCG (u-hCG) + Follitropin alpha is a phase 3 stage product being developed by Merck for Anovulation. The current trial status is completed. This product is registered under clinical trial identifier NCT01653743. Target conditions include Anovulation, Oligo-ovulation, Hypothalamic-pituitary Dysfunction.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01653743 | Phase 3 | Completed |
Competing Products
3 competing products in Anovulation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Orlistat Vs Metformin | Roche | Pre-clinical | 23 |
| usual administration of exogenous recombinant FSH | Organon | Pre-clinical | 18 |
| Follitropin beta | Organon | Pre-clinical | 18 |